J
Jiejun Wang
Researcher at Second Military Medical University
Publications - 19
Citations - 5652
Jiejun Wang is an academic researcher from Second Military Medical University. The author has contributed to research in topics: Cancer & Carcinogenesis. The author has an hindex of 13, co-authored 19 publications receiving 4915 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng-Long Ye,Tsai Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis,Zhongzhen Guan +20 more
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
Journal ArticleDOI
Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer.
Guanzhen Yu,Jiejun Wang,Ying Chen,Xi Wang,Jun Pan,Gang Li,Zhiliang Jia,Qiang Li,James C. Yao,Keping Xie +9 more
TL;DR: Increased activation of mTOR is frequent in human gastric cancer and overexpression of p-mTOR is an independent prognostic factor, suggesting that mTOR pathway could be a potential target for therapy of this malignancy.
Journal ArticleDOI
[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].
Jinwan Wang,Yan Sun,Yong Yu Liu,Qitao Yu,Yiping Zhang,Kai Li,Yun-zhong Zhu,Qinghua Zhou,Mei Hou,Zhongzhen Guan,Weilian Li,Wu Zhuang,Donglin Wang,Houjie Liang,Fengzhan Qin,Huishan Lu,Xiaoqing Liu,Hong Sun,Yanjun Zhang,Jiejun Wang,Suxia Luo,Ruihe Yang,Yuanrong Tu,X. Wang,Shu-ping Song,Jingmin Zhou,Li-fen You,Jing Wang,Chen Yao +28 more
TL;DR: The addition of YH-16 to NP regimen results in significantly and clinically meaningful improvement in response rate, median time to tumor progression, and clinical benefit rate compared with NP alone in advanced NSCLC patients.
Journal ArticleDOI
Downregulation of metastasis suppressor 1(MTSS1) is associated with nodal metastasis and poor outcome in Chinese patients with gastric cancer.
TL;DR: M TSS1 expression decreased significantly as gastric cancer progressed and metastasized, suggesting MTSS1 may serve as a useful biomarker for the prediction of outcome of gastriccancer.
Journal ArticleDOI
Expression profile and prognostic role of sex hormone receptors in gastric cancer
TL;DR: The findings indicate that the sex hormone receptors may be partly involved in Gastric carcinogenesis but their clinicopathological and prognostic significance in gastric cancer appears to be limited.